Clinical-stage immuno-oncology company Affimed N.V. (Nasdaq:AFMD) reported on Wednesday that the first patient has been dosed in the first-in-human clinical trial of the innate cell engager (ICE) AFM28.
The phase 1 multicentre, open label, dose escalation study is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of AFM28 monotherapy in patients with CD123-positive (r/r) acute myeloid leukaemia (AML).
AFM28 directs natural killer (NK) cells to CD123-positive leukaemic cells, including blasts and leukaemic stem and progenitor cells, inducing their depletion in samples of patients with AML and myelodysplastic syndrome (MDS).
Affimed also intends to develop AFM28 in combination with allogeneic NK cell therapy.
Palatin presents symptom resolution data from Phase 3 dry eye disease trial
BioArctic expands exidavnemab trial to include Multiple System Atrophy patients
NeuroSense Therapeutics completes PrimeC commercial manufacturing scale-up
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics